F.D.A. panel sharply criticizes evidence that a closely-watched Alzheimer’s drug, Biogen's aducanumab, slows cognitive decline. “There are literally a dozen different red threads that suggest concerns about the consistency of evidence,” one expert said.

I fully agree with you. The Abeta hypothesis has been challenged by many people including us. I am a brain scientist studying the critical roles of reactive astrocytes in AD. We have a Nature Neurosci paper to be published on Nov. 16th on the reasons for failures of AD drugs.

Just joined the twitter! Please follow!